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Abstract 
Study Objective: To identify the characteristics associated with patients who improved in 
glycemic control versus those who did not, in response to the ENGAGE-DM trial intervention. 
Methods: The ENGAGE-DM intervention consisted of a shared decision-making and brief 
negotiated interview session delivered over the telephone to improve glycemic control. This is a 
secondary analysis of variables from the pharmacist notes recorded during the interview and 
insurance claims data for the patients in the intervention group (n=155). Statistical analyses were 
used to test associations between the variables under study and glycemic control improvement. 
Descriptive analyses were conducted to compare positive and negative deviants, as well as key 
barriers and themes surrounding diabetes management. 
Findings: Patients that experienced substantial improvements in HbA1c were more likely to be 
male (p=0.008), be a part of a female pharmacist-male patient concordant pair (p=0.04), have a 
high baseline HbA1c value (p=0.00003), and report higher readiness to change their behavior 
(p=0.08). Barriers to successful diabetes management most frequently cited by patients were 
related to work commitments, comorbidities, and cost of medications and test supplies. 
Conclusions: This study demonstrated that important gender differences in diabetes 
management influence the extent to which women and men improve from an intervention. These 
findings emphasize the importance of stratifying analyses by gender to understand an 






  Type 2 diabetes mellitus (T2DM) is a severe, costly disease of increasing prevalence and 
consequence for both patients and the healthcare system at large. Diagnosed diabetes currently 
affects over 9% of the U.S. population and annually costs $327 billion in direct medical costs 
and reduced productivity.1,2 Diabetes is associated with major macrovascular complications and 
is consequently the seventh leading cause of the death in the U.S.1 Optimal glycemic control has 
been shown to significantly reduce these complications and risk for mortality. However, despite 
new drugs and technologies to manage diabetes, patients still fail to meet glycemic targets.3 
Major reasons for a patient’s inability to reach glycemic targets are attributable to 
preventable provider and patient behavior.3 Providers often fail to intensify treatment for a 
patient with poor glycemic control according to evidence-based guidelines.4 Several studies 
indicate that between about 60-80% of patients with poor control have suboptimal regimens, as a 
result of clinical inertia.5,6 This is compounded by poor patient adherence to medication regimens 
and lifestyle modification recommendations necessary for glycemic control.7 Studies have 
demonstrated adherence rates of 50% or lower for a wide variety of chronic conditions.7  Many 
interventions have sought to address clinical inertia or patient adherence with varying success in 
improving glycemic control.8 
There are several potential reasons for why existing interventions for patients with 
diabetes may have limited effects for some patients. A patient’s response to an intervention may 
be impeded by work or family commitments, costs of medication, limited access to medication, 
medication side effects, and comorbidities.7 In addition, a patient’s response may depend on their 
willingness to change their behavior or characteristics related to how the intervention was 
delivered.9-11 It is unclear how these factors interact, driving some patients to improve 
substantially upon intervention while impeding others. Therefore, it is necessary to conduct 
analysis of interventions to evaluate the reasons why patients may benefit differentially. 
We aimed to explore these factors using data from the ENGAGE-DM (ENhancing 
outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus) trial. 
ENGAGE-DM was a pragmatic trial of 1400 patients with poorly-controlled diabetes 
randomized to intervention or usual care.9,10 The intervention was delivered over the telephone 
by a pharmacist and integrated brief negotiated interviewing and shared decision-making to 
identify patient-concordant goals for improving patients' lifestyle diabetes management, 
addressing medication adherence issues, and facilitating choices for treatment intensification by 
the provider to address clinical inertia. Pharmacist notes summarized the telephone conversation 
with each patient. The trial's primary outcome was disease control, which was assessed using 
glycated hemoglobin (HbA1c) values, in addition to secondary outcome measures of medication 
adherence. There were no differences in glycemic control between the intervention and control 
arm at the population level, but individual differences were noted in exploratory analyses in 
some subgroups. It is unclear why certain patients improved substantially while others did not. 
Therefore, we will conduct a secondary analysis of the trial data to address the following 
research questions: 
What are the common factors associated with patients who experienced substantial 
improvements in glycemic control versus those who did not in response to the ENGAGE-DM 
intervention? 




Researchers have proposed various reasons for differing treatment effects across patient 
subgroups and limitations of interventions similar to the ENGAGE-DM trial. 
Studies suggest that although patients with diabetes may document more self-
management goals and have an increased understanding of their condition in response to an 
intervention, they vary substantially in whether they actually attain these goals successfully. A 
study of a brief shared decision-making goal-setting intervention among individuals with type 2 
diabetes demonstrated statistically significant improvements in patients’ understanding of 
diabetes and mean number of documented self-management goals (0.67 goals pre-intervention to 
1.09 goals post-intervention), with no improvements in blood glucose levels.11 Yet, patients may 
substantially vary in whether they successfully adhere to these goals. Tuomilehto et al. estimate 
this adherence to range from as low as 25% completion of diet-related goals to 86% completion 
of exercise-related goals.12 Additionally, Lindström et al. state that only 14% and 6% of 
participants in the Finnish Diabetes Prevention Study completed all four or five of their stated 
goals, respectively.13 Other analyses have shown that adherence to stated goals is significantly 
associated with a decreased incidence of diabetes, with an 89% risk reduction among patient 
subgroups meeting all of their state goals.14 These findings show that an intervention’s ability to 
improve a clinical outcome like glycemic control may be mediated by a patient’s ability to 
adhere to the shared decision-making goals set forth during the intervention. 
Studies also suggest that patients’ baseline levels of health behavior adoption and 
readiness to change their health behavior may limit intervention effects. A lifestyle modification 
intervention aiming to increase glycemic control and weight loss found a 76% risk reduction of 
diabetes incidence for patients with lower baseline glucose concentrations, which was 
statistically significantly greater than the 50% risk reduction for those with higher baseline 
glucose values.15 Alternatively, a multicenter trial of motivational interviewing in teenagers with 
diabetes proposed that the limited effect of their intervention may have been due to a lack of 
adequate exclusion of patients who had high glycemic control at baseline. Researchers also 
observed that the inclusion of patients in their sample who had low readiness to change was a 
potentially limiting factor, because they assumed providers had already persuaded patients that 
the behavioral change was important and within their ability.16 A telecare peer-delivered 
intervention for diabetes motivation and support similarly failed to significantly affect clinical 
outcomes, which was unexplained by subgroup differences. They attributed these results, in part, 
to a lack of adequate exclusion of patients who had low readiness to change.17 Furthermore, 
literature reviews reiterate that motivational interviewing techniques are limited in their ability to 
affect behavioral change if patients do not feel confident in their ability to change or do not think 
that it is important.18 
Several trials cite the relative inexperience or insufficient training of implementers of the 
intervention as a limiting factor because it may lead to incomplete or inconsistent 
implementation. Researchers in the aforementioned telecare peer-delivered intervention 
suggested that providers of the intervention may not have been trained fully and consistently 
enough to successfully implement the intervention.17 A brief telephone intervention by 
paraprofessionals for type 2 diabetes failed to find a significant reduction in HbA1c levels, and 
the authors suggested this was partially due to inexperienced or inconsistently trained coaches.19 
They also cited other factors including the brevity and semi-structured nature of the coaching 
intervention and noted that improvements in outcomes immediately following the intervention 
may not be adequately sustained and detected at follow-up.19  
Sacco et al. propose several research questions for future studies, including whether 
similar interventions are limited by characteristics of the intervention (e.g. too intrusive, too 
many sessions over too many weeks), characteristics of the coach (e.g. inexperience), or whether 
life events conflicted with the requirements of the intervention (e.g., too busy, family and life 
crises, co-morbidities).19 These studies present several potential avenues and context within 




This study used a mixed methods design to determine the variables that have a greater 
association with patients who improved in glycemic control in response to the intervention 
versus those who did not. This study will primarily use Mohr’s variance theory, which aims to 
examine outcomes in the context of contemporaneous predictor variables.20 
 
Participants and sampling methods 
The ENGAGE-DM trial’s study population consisted of commercially-insured 
individuals whose medical and prescription benefits were administered by Horizon Blue Cross 
Blue Shield of New Jersey. Patients who met the inclusion criteria were ≥18 years of age, had 
filled a prescription for 1 or more oral hypoglycemic agents within the prior 12 months, and had 
evidence of poor glycemic control (HbA1c ≥ 8%) within the previous 6 months. These patients 
were randomized in a 1:1 ratio to intervention and control groups using a random number 
generator (Appendix: Figure 1). Of the 700 patients assigned to the intervention group, 202 
(29%) consented to participate in the intervention. Patients who were not successfully contacted 
(n=9) or had missing HbA1c data (n=38) were excluded, and the remaining 155 patients 
comprised the sample for this study. Prior analysis of the trial data found no difference in 
findings between complete case analyses and those using multiple imputation to account for 
missing data. 
 
Research methods and data sources 
The data source for this secondary analysis is the ENGAGE-DM trial. The intervention 
consisted of a semi-structured telephonic encounter with the patient combining shared decision 
making and brief negotiated interview techniques, conducted by pharmacists using an interview 
call guide (Appendix: Figure 2).21,22 
The semi-structured call guide included a review of study medications and discussed the 
issue of poor glycemic control. Brief negotiated interviewing was used to elicit patient 
perceptions about the challenges of managing diabetes and how patients are already managing 
their condition through exercise, diet, medication adherence, and blood glucose testing. The 
pharmacist and patient then made a shared decision about whether the patient should pursue the 
treatment intensification or lifestyle modification path to improve their glycemic control. If the 
treatment intensification was chosen, the pharmacist and patient made additional shared 
decisions about potential treatment options to recommend to the physician. If the lifestyle 
modification path was chosen, brief negotiated interviewing tactics were used to elicit barriers to 
behavior change and how to address them. These discussions would culminate in the negotiation 
of a plan of action for the patient in order to implement the changes discussed for their chosen 
path. To conclude the conversation, the pharmacist asked the patient about their readiness to 
change their behavior and offered written and online resources for the patient to reference 
moving forward. 
After each session, the pharmacist recorded the major goals, decisions, and topics 
discussed. This included direct quotations from patients and paraphrased patient comments in 
response to the outline of the call guide. Insurance claims data was also available for each patient 
for the duration of the trial. This study analyzed variables from both the pharmacist notes and the 
insurance claims data. 
 
Data analysis methods 
The 7 stages of data analysis of the framework method developed by Gale et al. were 
used to analyze the pharmacist notes for each patient.23 This included transcription of the data, 
familiarization with the interview, inductive coding, developing a working analytical framework, 
applying the analytical framework, charting the data into a framework matrix, and finally 
interpreting the data. Through these analysis stages, major categories of information addressed in 
the call guide and recorded in the pharmacist notes were extracted into a matrix.24 The analyzed 
notes were divided into two subgroups: patients who improved glycemic control in response to 
the intervention and those who did not. These variables were summarized numerically in counts 
or descriptively through quotations. 
A deviance analysis was performed on patients in the top 2.5th and bottom 2.5th percentile 
of glycemic control improvement. Common factors unique to positive and negative deviants 
were recorded. Patient reported barriers and other significant themes were notated through both 
numerical counts and direct quotations. 
Variables from both the insurance claims data for each patient and significant variables in 
the pharmacist notes were evaluated quantitatively. Student’s t tests were used to detect 
differences in HbA1c outcomes for binary variables. One-way analysis of variance (ANOVA) 
tests were used to determine whether there were statistically significant differences in HbA1c 
outcomes in variables with three or more levels in their narrative, such as concordance and the 
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In total, 193 patients with diabetes completed the pharmacist interview in the intervention 
group. Patients with missing HbA1c level data (n=38) were excluded, and the remaining 155 
patients were included in the final sample for this study. 60.6% (n=94) of the patients were male 
and 56.8% (n=88) were over the age of 55. Patient and intervention characteristics are 
summarized in Table 1. Patients are grouped by whether their HbA1c level improved from 
baseline after the intervention. 
  
Table 1: Patient and intervention characteristics by improvement in HbA1c 
  Improved HbA1c, n (%) HbA1c Change 
Mean (SD) 
 
Variables Total, n (%) No Yes P-value 
Total 155 (100) 45 (29.0) 110 (71.0) -0.92 (1.90)  
Age 
>55 88 (56.8) 34 (75.6) 54 (49.1) -0.52 (1.61) 0.162 
≤55 67 (43.2) 11 (24.4) 56 (50.9) -1.45 (2.13)  
Patient Gender 
Female 61 (39.4) 24 (53.3) 37 (33.6) -0.33 (1.48) 0.008a 
Male 94 (60.6) 21 (46.7) 73 (66.4) -1.30 (2.05)  
No. of oral hypoglycemics 
≥2 111 (71.6) 32 (71.1) 79 (71.8) -1.02 (1.94) 0.292 
<2 44 (28.4) 13 (28.9) 31 (28.2) -0.67 (1.81)  
Type of medication 
Brand only 21 (13.5) 7 (15.6) 14 (12.7) -0.30 (1.62) 0.243b 
Generic only 76 (49.0) 21 (46.7) 55 (50.0) -1.08 (1.93)  
Mixture 58 (37.4) 17 (37.8) 41 (37.3) -0.94 (1.94)  
Optimal Adherence (PDC) 
Yes 123 (79.4) 34 (75.6) 89 (80.9) -1.08 (1.81) 0.042a 
No 32 (20.6) 11 (24.4) 21 (19.1) -0.32 (2.15)  
Self-Reported Adherent Behavior 
Yes 60 (38.7) 18 (40.0) 42 (38.2) -1.11 (2.12) 0.336 
No 95 (61.3) 27 (60.0) 68 (61.8) -0.81 (1.76)  
Concordance (Patient-Pharmacist)c 
Female-Female 21 (14.7) 9 (22.5) 12 (11.7) -0.62 (1.33) 0.040a,b 
Male-Male 64 (44.8) 13 (32.5) 51 (49.5) -1.23 (1.80)  
Male-Female 23 (16.1) 6 (15.0) 17 (16.5) -1.43 (2.67)  
Female-Male 35 (24.5) 12 (30.0) 23 (22.3) -0.26 (1.51)  
Concordancec 
Yes 85 (59.4) 22 (55.0) 63 (61.2) -1.08 (1.71) 0.265 
No 58 (40.6) 18 (45.0) 40 (38.8) -0.72 (2.10)  
Pharmacist Genderc 
Female 44 (30.8) 15 (37.5) 29 (28.2) -1.04 (2.15) 0.651 
Male 99 (69.2) 25 (62.5) 74 (71.8) -0.89 (1.76)  
Shared Decision 
Lifestyle - Adherence 22 (14.2) 5 (11.1) 17 (15.5) -1.1 (1.56) 0.294b 
Lifestyle - Diet/Exercise 68 (43.9) 17 (37.8) 51 (46.4) -1.18 (2.23)  
Treatment Modifications 22 (14.2) 8 (17.8) 14 (12.7) -0.38 (1.68)  
Not Ready 43 (27.7) 15 (33.3) 28 (25.5) -0.71 (1.54)  
No. of pharmacist calls 
>1 90 (58.1) 28 (62.2) 62 (56.4) -0.84 (1.92) 0.510 
1 65 (41.9) 17 (37.8) 48 (43.6) -1.04 (1.88)  
Pillbox used 
Yes 29 (47.5) 10 (55.6) 19 (44.2) -0.49 (1.66) 0.166 
No 32 (52.5) 8 (44.4) 24 (55.8) -1.11 (1.80)  
Dietd 
Yes 96 (68.6) 26 (66.7) 70 (69.3) -0.97 (2.01) 0.713 
No 44 (31.4) 13 (33.3) 31 (30.7) -0.84 (1.62)  
Exercised 
Yes 90 (64.7) 22 (56.4) 68 (68.0) -0.98 (1.86) 0.625 
No 49 (35.3) 17 (43.6) 32 (32.0) -0.81 (1.98)  
Self-monitoringd 
Yes 91 (68.9) 26 (68.4) 65 (69.1) -0.89 (1.96) 0.822 
No 41 (31.1) 12 (31.6) 29 (30.9) -0.97 (1.78)  
Medication adherenced 
Yes 101 (74.8) 29 (78.4) 72 (73.5) -0.96 (2.01) 0.976 
No 34 (25.2) 8 (21.6) 26 (26.5) -0.95 (1.51)  
Treatment recently changedd 
Yes 36 (25.5) 11 (28.2) 25 (24.5) -1.21 (1.82) 0.347 
No 105 (74.5) 28 (71.8) 77 (75.5) -0.87 (1.90)  
Readiness to Change (0-10)d 
>5 43 (79.6) 9 (75.0) 34 (81.0) -0.91 (1.55) 0.084 
≤5 11 (20.4) 3 (25.0) 8 (19.0) -0.05 (0.94)  
ap<0.05 
bAn ANOVA test was performed to assess this p-value. Pairwise comparisons were conducted 
using T-tests: Brand vs. Generic Medications (p=0.091), F-M vs. M-M (p=0.008), F-M vs. M-F 
(p=0.038), F-F vs. M-M (p=0.160), F-F vs. M-F (p=0.221), F-F vs. F-M (p=0.366), M-F vs. M-
M (p=0.699), Diet/Exercise Arm vs. Treatment Modifications (p=0.128), Adherence Arm vs. 
Treatment Modifications (p=0.146). 
cn=143 because of missing pharmacist gender data. 
dn < 155 because some patients did not report on all variables measured from the pharmacist 
interview. 
	
On average, men made significantly larger HbA1c improvements (Mean: -1.30, SD: 
2.05) than women (Mean: -0.33, SD: 1.48) after the intervention (p=0.008). Patients who reached 
optimal medication adherence, defined as having greater than 80% proportion of days covered 
post-intervention, were also significantly more likely to improve (p=0.04). An ANOVA test of 
patient-pharmacist gender concordance revealed that concordance varied with HbA1c 
improvement (p=0.04). Male patients interviewed by a female pharmacist had the largest mean 
HbA1c improvements of -1.43 (SD: 2.67) while female patients interviewed by a male 
pharmacist improved the least by -0.26 (SD: 1.51) (p=0.04). Although not statistically 
significant, female patients with a female pharmacist trended towards smaller HbA1c 
improvements than male patients with a male pharmacist (p=0.16). In addition, patients who 
reported higher readiness to change were more likely to improve (p=0.08). 
Table 2 presents data collected from the Horizon Blue Cross Blue Shield claims database 
and information coded from the pharmacist interviews. Patients who improved had a baseline 
HbA1c value of 9.53 (SD: 1.69) which was significantly higher than that of patients who did not 
improve with a baseline of 8.37 (SD: 0.99) (p=0.0003). This difference is mirrored in both the 
latest value measured and the mean value of all measurements in the baseline period. Patients 
who improved had an average PDC of 89.9, higher than that of those who did not improve which 
was 83.4 (p=0.09). Patients with diabetes who did not improve who more likely to have 
comorbidities including coronary artery disease (p=0.05), COPD/Asthma (p=0.04), Depression 
(p=0.04). Interestingly, obesity was more prevalent in those who improved (p=0.02). With regard 
to resource utilization, patients who improved had notably less ER visits during the baseline 
period (p=0.03). 
  
Table 2: Variables under study by improvement group 
 
Improved HbA1c  
Yes No P-value 
Baseline HbA1c, mean (SD) 
Latest HbA1c value 9.53 (1.69) 8.37 (0.99) 0.00003a 
Mean HbA1c value 9.47 (1.63) 8.59 (0.94) 0.0009a 
Medication, mean (SD) 
No. oral hypoglycemics 2.07 (0.92) 2.07 (0.99) 0.971 
Adherence (PDC) 89.87 (17.87) 83.40 (28.50) 0.091 
Copayments 27.58 (45.76) 41.94 (95.62) 0.216 
Diabetes Characteristics, % (SD) 
Ketoacidosis 48.2 (50.0) 46.7 (49.9) 0.865 
Nephropathy 0.9 (9.5) 0 (0) 0.524 
Neuropathy 55.5 (49.7) 48.9 (50.0) 0.460 
Retinopathy 1.8 (13.4) 4.4 (20.6) 0.352 
Other Clinical Characteristics, % (SD) 
Acute Stress 2.7 (16.3) 0 (0) 0.266 
Alcohol Use 13.6 (34.3) 6.7 (24.9) 0.222 
Coronary Artery Disease 11.8 (32.3) 24.4 (43.0) 0.049a 
Congestive Heart Failure 4.5 (20.8) 0 (0) 0.148 
Chronic Kidney Disease 49.1 (50.0) 51.1 (50.0) 0.821 
COPD/Asthma 8.2 (27.4) 20.0 (40.0) 0.037a 
Depression 0.9 (9.5) 6.7 (24.9) 0.040a 
Hyperlipidemia 76.4 (42.5) 62.2 (48.5) 0.075 
Hypertension 66.4 (47.2) 77.8 (41.6) 0.163 
Liver Disease 6.4 (24.4) 8.9 (28.5) 0.581 
Obesity 30.9 (46.2) 13.3 (34.0) 0.023a 
Osteoporosis 2.7 (16.3) 2.2 (14.7) 0.858 
Stroke/TIA 6.4 (24.4) 11.1 (31.4) 0.319 
Tobacco 1.8 (13.4) 0 (0) 0.366 
Resource Utilization, mean (SD) 
No. of days hospitalized 0.62 (4.73) 0.60 (3.35) 0.981 
ER visits 0.16 (0.46) 0.38 (0.72) 0.028a 
Office Visits 7.83 (5.62) 8.53 (5.32) 0.472 
Self-Reported Barriers, % (SD) 
Family 3.9 (19.4) 2.5 (15.8) 0.689 
Comorbidities 25.2 (43.7) 17.5 (38.5) 0.327 
Work 22.3 (41.9) 20.0 (40.5) 0.764 
Time 5.8 (23.5) 10.0 (30.4) 0.383 
Cost 11.7 (32.2) 10.0 (30.4) 0.781 
Medication Side Effects 4.9 (21.6) 12.5 (33.5) 0.109 
Cultural 2.9 (16.9) 0 (0) 0.279 
ap<0.05 
	
Table 3 presents the relationship between gender and the other variables related to 
HbA1c improvement examined in this study. Women on average had a lower baseline HbA1c 
value of 8.86 (SD: 1.11) than men who had an average baseline of 9.41 (SD: 1.83) (p=0.04). This 
is reflected in both the latest baseline value measured and the mean of the measurements taken in 
the baseline period. In the pharmacist interviews, women were more likely to report a family 
commitment as a barrier to their diabetes management (p=0.02). 
Several trends were noted in other variables.  Notably, women were less likely to report 
exercising to manage their diabetes (p=0.08) and reported lower levels of readiness to change 
their behaviors (0.07). Men tended to self-report medication adherence more frequently than 
women (p=0.06). Men more frequently reported work as a barrier (p=0.15) while women had 
more reports of medication side effects (p=0.12) and comorbidities (p=0.06) as impeding their 
ability to manage their diabetes. Figures 1-3 summarize the findings for the relationship between 
gender and key factors and barriers of diabetes management. 
  
Table 3: The relationship between gender and variables under study 
 Female Male P-Value 
Baseline HbA1c, mean (SD) 
Latest HbA1c value 8.86 (1.11) 9.41 (1.83) 0.039a 
Mean HbA1c value 8.93 (1.13) 9.40 (1.69) 0.059 
Medication, mean (SD) 
Adherence (self-reported) 29.5 (46.0) 44.7 (50.0) 0.059 
Adherence (PDC) 85.83 (24.54) 89.39 (19.47) 0.318 
Brand medications 11.5 (31.9) 14.9 (35.6) 0.547 
Generic medications 55.7 (49.7) 44.7 (49.7) 0.181 
Diabetes Characteristics, % (SD) 
Ketoacidosis 41.0 (49.2) 52.1 (50.0) 0.177 
Nephropathy 1.6 (12.7) 0 (0) 0.216 
Neuropathy 45.9 (49.8) 58.5 (49.3) 0.126 
Retinopathy 1.6 (12.7) 3.2 (17.6) 0.555 
Other Clinical Characteristics, % (SD) 
Acute Stress 3.3 (17.8) 1.1 (10.3) 0.331 
Alcohol Use 6.6 (24.8) 14.9 (35.6) 0.115 
Coronary Artery Disease 11.5 (31.9) 18.1 (38.5) 0.269 
Congestive Heart Failure 0 (0) 5.3 (22.4) 0.068 
Chronic Kidney Disease 42.6 (49.5) 54.3 (49.8) 0.159 
COPD/Asthma 16.4 (37.0) 8.5 (27.9) 0.136 
Depression 3.3 (17.8) 2.1 (14.4) 0.661 
Hyperlipidemia 68.9 (46.3) 74.5 (43.6) 0.449 
Hypertension 72.1 (44.8) 68.1 (46.6) 0.595 
Liver Disease 8.2 (27.4) 6.4 (24.4) 0.670 
Obesity 24.6 (43.1) 26.6 (44.2) 0.782 
Osteoporosis 3.3 (17.8) 2.1 (14.4) 0.661 
Stroke/TIA 4.9 (21.6) 9.6 (29.4) 0.292 
Tobacco 0 (0) 2.1 (14.4) 0.254 
Resource Utilization, mean (SD) 
ER visits 0.20 (0.44) 0.24 (0.61) 0.600 
Self-reported behaviors, % (SD) 
Diet 66.1 (51.4) 74.7 (48.7) 0.313 
Exercise 58.9 (53.2) 74.7 (51.1) 0.078 
Self-monitoring 76.8 (60.3) 80.5 (54.6) 0.408 
Readiness to Change >5 71.0 (45.4) 91.3 (28.2) 0.069 
Self-reported barriers, % (SD) 
Family 7.8 (27.0) 0.9 (9.6) 0.015a 
Comorbidities 31.2 (46.6) 19.3 (39.6) 0.062 
Work 13.0 (33.8) 21.1 (41.0) 0.155 
Time 5.2 (22.3) 6.4 (24.6) 0.729 
Cost 10.4 (30.7) 11.9 (32.6) 0.746 
Medication Side Effects 9.1 (28.9) 3.7 (18.9) 0.124 








































































































































































Positive and Negative Deviance Analysis 
The mean HbA1c change in the intervention group was -0.92 (SD: 1.90). There were 6 patients 
who had HbA1c changes from baseline to post-intervention that were greater than 2 standard 
deviations away from the mean in the top 2.5 percentile [-7.7, -7.3, -6.3, -6.1, -4.8, -4.7]. There 
were 2 patients with HbA1c changes in the bottom 2.5 percentile [3.9, 4.8]. Intervention 




1. Already made changes to adopt a strong diet, exercise, medication adherence, and/or self-
monitoring regimen. 
“He lost 40 pounds by completely changing his diet. He has oatmeal with berries, whole 
wheat, egg whites, and lean meats.” 
 “To manage his diabetes the member has a strict diet. He tries to avoid sugar and has a 
high protein/low carb diet. He has lost about 31 pounds.” 
“In term of exercise, the member walks about 3-4 miles a day for his job.” 
“He has a system using plastic bags and organizes [his medication] for 2 weeks.” 
 “She tests her blood sugar 3 times a day and her number she says have been good, 
around 150-175.” 
2. Compelling reasons to change their behavior. 
 “She was recently hospitalized because her blood sugar was so high. She saw this as a 
reason to start getting more on top of her disease.”  
3. Shared decision was to continue the same activities, because they are already successfully 
making changes. 
“He is already doing a lot of lifestyle changes,” and therefore the pharmacist 
“encouraged him to continue doing what he is doing.” 
“Tried to discuss exercise a bit more but he feels what he does at his job is enough.” “He 
was not ready to make more changes but he is already on the diet/lifestyle path.” 
4. High baseline HbA1c values. [11.4, 13.6, 11.5,  13.4, 12.2, 15.9] 
5. High PDC post-intervention. [100, 95.63, 95.63, 100, 91.26] 
6. High self-efficacy and engagement. 
“She seems committed to changing. I asked her on a scale of 1-10 how ready she is, and 
she said 10.” "I will do anything to help myself." 
“Discussed seeing a nutritionist and he was open to doing this. He said he was at a 10. 
Also provided the website diabetes.org which he was happy to write down.” 
7. Shared Decision. All 6 positive deviants chose the Lifestyle Modifications - Diet/Exercise arm 
of the intervention. 
 
Negative Deviants: 
1. Poor diet, exercise, medication adherence, or self-monitoring regimen. 
 “He does not follow a specific diet or meal plan.” 
“He denies missing any doses,” however his PDC is not optimal at 16.39. 
2. Low engagement with the intervention or readiness to change behavior. 
“When presented with the 2 choices he was not ready to make a change, he thinks he is 
under good control and likes the way things are,” although his blood sugar readings are 
in fact high. 
“He is not going to change anything at this time and would like a call back in May.” 
3. Low and borderline baseline HbA1c values. [8.8, 8.1] 




Work, comorbidities, family commitments, time, cost, medication side effects, and cultural 
reasons were the main recurring barriers patients cited in the pharmacist interview as interfering 
with their ability to successfully manage their diabetes (Table 4). 
Table 4: Patient-reported barriers (n=192) 
 n (%) 
Work 34 (17.7) 
Comorbidities 45 (23.4) 
Family 7 (3.6) 
Time 11 (5.7) 
Cost 21 (10.9) 
Medication Side Effects 11 (5.7) 
Cultural 5 (2.6) 






Strenuous work schedules, late or nightly work shifts, and occupations that required long periods 
of driving or sitting down hindered patients’ ability to find time to exercise, cook healthy food, 
and schedule appointments with a doctor or nutritionist. 
“He is on the road all day for his job so he has to stop at places like 7-11 for food . . . He 
finds it hard to exercise since he is confined to his car for most of the day.  When he gets 
home he finds that he loses the motivation to go walking or do any exercise.” 
“He finds it hard to exercise because he works 2 jobs.  The jobs are active and involve a 
lot of walking, but leave no time for structured exercise. His doctor recommended seeing 
a nutritionist as well but he doesn't have the time on his current work schedule.”	
	
A patient’s occupation could also make it difficult to adhere to their medication regimen and test 
their blood sugar at the recommended frequency. 
“He is a long-haul truck driver and drives across country frequently. The hardest part 
about managing his diabetes is his job. He states he has not tested his blood sugar in a 
couple weeks. He says it's hard to test when he's on the road.” 
“He states he is not taking repaglinide TID because he does not always have 3 meals a 
day with his job (he said he is a driver).”  
 
Comorbidities 
In this sample, 23.4% of patients reported that a comorbidity was interfering their diabetes 
management, particularly by physically restricting their ability to exercise. A large portion of 
patients reported back and knee issues, sometimes in conjunction with arthritis, that limited their 
activity. 
“She states she has bad fibromyalgia and if that flares up it’s tough for her to get out and 
exercise.” 
“Exercise is the hardest part for him due to peripheral neuropathy.” 
“She is unable to exercise much due to knee problems.” 
“She states she lives alone, battles depression and really doesn't have much motivation 
for taking care of herself." 
 
Family 
Several patients explained that a family commitment, such as taking care of a child or parent, 
was limiting their ability to find time to exercise or seek care. 
"Her mother is currently in the hospital and this had been hard for her to stay on track. 
She says right now she really does not have time to walk or exercise. " 
“She currently isn't getting a lot of exercise as she watches her baby grand daughter and 
is limited to her house right now. As the baby grows, so will her activity level.  She 




Time was cited frequently as a barrier mainly to exercising. 
“To better manage his diabetes, the member is trying to eat healthy and exercise but 
finding time to exercise is the hardest part.” 
“He stated time was his biggest obstacle to monitoring his BS daily and exercising.” 
 
Cost 
Cost was an important recurring barrier to obtaining medication and self-monitoring supplies. 
Patients experienced difficulties buying medications that were not adequately covered by their 
Horizon BCBSNJ plan, despite the benefit these medications had for their diabetes management. 
"She trialed Januvia 100mg QD, but could not afford to stick with it.  She reports that it 
helped her BS, but the cost was too much.” 
“He isn't currently testing his BS as he has no test strips for his One Touch Vario IQ 
meter. The strips were 90.00 at the pharmacy.” 
“The hardest part is obtaining his insulin. He is having a hard time getting them. They 
need a PA and the cost runs him out." 
“He is not taking Farxiga because when he went to pick up this medication it was $900 
for a 3 month supply.” 
  
Patients did not see nutritionists and seek specialist care because of high costs. 
“Cost is an issue for her and she mentioned she has a 50.00 copay vs. 30.00 for an 
endocrinologist and PCP respectively. She wants to go to a PCP only." 
“She seemed opposed to going to see a nutritionist mainly due to cost." 
 
Affording gym memberships and healthy food as opposed to fast food made it difficult for 
patients to adhere to optimal diet and exercise regimens. 
“Dieting is difficult for him because he does not have a kitchen so he cannot cook.  He 
has to go find food most of the time and finds that he is still hungry after eating.  He has 
seen a nutritionist who suggested he look for a specific frozen dinner that is low in salt 
and sugar, but it is hard to find and expensive.” 
“It was too expensive to get healthy food every few days. She works 40 hours a week and 
gets home late and it was too much of a commitment. She does not like to go to the gym 
and it costs too much money." 
 
Medication Side Effects 
Medication side effects predominantly reduced patients’ adherence to their medications. 
"Member is currently not taking Metformin 500mg 2 tabs (1000 mg) po BID due to 
nausea and diarrhea." 
“He states he has stopped taking his metformin due to the fact he is getting very bad 
diarrhea because of it.” 
 
Cultural 
Patients had dietary habits reinforced by their culture and community that made it hard to adopt 
the dietary recommendations for diabetics. 
“She is Colombian so the types of foods they eat make it challenging.” 
“Food is the hardest part about managing his diabetes, as he is Puerto Rican and loves 
his rice and beans. He reports since coming to the States, his lifestyle and eating habits 
have changed. He has gained weight since coming and noted diabetes runs in his 
family.” 
“The member is trying to eat healthy . . . he said he is African and a lot of the cultural 
dishes have carbs but he tries to limit it.” 
“He states that since he is Polish he eats a lot of starches. He is aware of how they 
negatively affect his disease. He is trying to cut down on them.” 
 
Other Significant Themes 
1) Patients (n=23) cited weather as an important facilitator of or barrier to exercise. This was 
particularly a barrier for many patients who use walking as their primary mode of exercise. 
“In terms of exercise he tries to walk 30 minutes a day. The hardest part for him is that it 
is winter and that prevents him from being about to walk a lot.” 
“She doesn't follow any specific diet and only walks for exercise which she states is a 
problem in the winter.” 
 
2) Patients (n=17) described their physically demanding job as their main source of exercise, 16 
of whom were male. 
“He works as a security guard and is constantly walking while on the job.  He finds this 
to be much more than the recommended 30 min 5x/week.” 
“In term of exercise, the member walks about 3-4 miles a day for his job. He is a factory 
rep.” 
“He states his job is very physically demanding. He works for an appliance company so 
he moves washing machines and refrigerators.” 
“His exercise is his work.  He is on his feet 50-60 hrs/wk walking and lifting objects and 
cannot fit any more into his schedule.” 
 
3) Patients stated most frequently that the hardest part of managing diabetes is the diet. Their 
responses (n=75)  are summarized in Table 5. 
Table 5: Patient responses about the hardest part of managing their diabetes during the 
pharmacist interview. 
n (%) “What is the hardest part of managing your diabetes?” 
53 (71) Diet, particularly for sugar and food cravings 
8 (11) Exercise, especially finding time to do it 
6 (8.0) Psychological aspects of dealing with diabetes, such as working hard to lower 
HbA1c with no positive results and coming to terms with actually having the 
disease 
6 (8.0) Self-monitoring their blood sugar through testing 
5 (6.6) Medication management, especially adhering to and obtaining it 
3 (4.0) Their job and work schedule 
2 (3.0) Managing their diabetes in addition to other comorbid conditions 
 
4) Patients (n=10) stated they are educated about the benefits of changing their behavior but have 
trouble actually implementing these changes. 
“He said he knows what he needs to do but doesn't do it.” 
“She said she knows she should be taking them every day,” however “she freely admits 
that she is not very consistent with taking the medication.” 
“He states he is aware of how to eat a good diet, but he does not have good discipline to 






In this study of 155 patients with poorly controlled diabetes receiving a pharmacist-led 
intervention, patients who experienced substantial improvements in HbA1c from the ENGAGE-
DM intervention were more likely to be male, be a part of a female pharmacist-male patient 
concordant pair, have a high baseline HbA1c value, and report higher readiness to change their 
behavior. Important barriers to successful diabetes management most frequently cited by patients 
were related to work commitments, comorbidities, and cost of medications and test supplies. 
This section synthesizes each of the major findings in the context of current literature, highlights 
the implications and limitations of this study, and suggests future directions in this area. 
 
Gender 
Gender differences in improvement in HbA1c, diabetes behaviors, and reported barriers 
were a main focus of this study’s findings. Men had a mean HbA1c level change of -1.30 
significantly higher than that of women, -0.33. Reasons for this gender difference may be related 
to how women and male engage in specific diabetes related behaviors. As summarized in Table 
3, men tended to report optimal diet, exercise (p=0.078), adherence (p=0.059) and self-
monitoring regimens more than women. Men were also more likely to report higher levels of 
readiness to change their behavior (p=0.069). 
A 2015 comprehensive review of the current evidence on sex and gender differences in 
diabetes risk, pathophysiology, and complications found that women with T2DM have a higher 
burden of risk factors and comorbidities, as well as physical and cognitive limitations than 
men.25 Additionally, women are more likely to be physically inactive than men. Several other 
diabetes management studies have found that men are more likely to exercise and improve their 
diet.26,27 In addition, a study on gender differences in diabetes self-management activities found 
that women were significantly more likely to report comorbidities and physical limitations that 
restrict their ability to perform optimal diabetes behaviors like diet and exercise relative to 
men.28 This is reflected in the findings of this study, as women tended to more frequently report 
comorbidities (p=0.062) in addition to medication side effects and family commitments 
(p=0.015) as barriers.  
Current literature shows a complex and unclear work-diabetes-stress risk relationship 
with gender.25 In this study, men tended to cite work commitments as a barrier and were also 
more likely to report using their occupation as a means for exercise more than women. This 
aligns with a review that found that having an active job and higher work demands has a 
protective effect for diabetic men, with little to no protection for women.25 The findings of this 
thesis both align with and identify gaps in current literature surrounding the relationship between 
gender and diabetes. 
 
Concordance 
Gender concordance was found to modify the intervention’s effect. Notably, female 
patients with male pharmacists were significantly less likely to improve their glycemic control 
than male patients with a female pharmacist. Literature suggests that the effects of concordance 
may be due to differences in the care given by the provider or disagreement by the patient about 
provider recommendations. For example, a study of obesity and weight management care found 
that male-male dyads were significantly more likely to receive optimal counseling on diet, 
exercise, and nutrition in comparison to female-female dyads.29 A study of disagreement 
between GPs and patients over weight loss, exercise, and nutrition recommendations found that 
disagreement was minimized in female-female dyads (OR=0.25, 95% CI=0.08–0.78) and female 
provider-male patient pairs (OR=0.24, 95% CI=0.07–0.80).30 The largest disagreement was 
found between female patients with male providers (OR=2.87, 95% CI=1.29–6.41).30 This 
study’s results closely mirror the findings of this thesis and suggest that levels of patient 
disagreement with provider recommendations may mediate the relationship between gender 
concordance and HbA1c level improvement. This is pertinent when assessing the effect of the 
ENGAGE-DM intervention in particular, as the trial tested the use of a shared decision between 
patient and provider, which relies on patient-provider agreement to achieve its effect. 
 
Baseline HbA1c Differences 
Analysis of the insurance claims data revealed that those who improved in HbA1c after 
the intervention had significantly higher baseline HbA1c values than those who did not 
(p=0.00003). This suggests the presence of a ceiling effect that limited the impact of this 
intervention for patients who had low or borderline diabetic HbA1c values. A 2010 Cochrane 
review of diabetes management interventions noted similar studies that were limited by a ceiling 
effect induced by enrollment of patients with low or borderline diabetic baseline HbA1c levels, 
reducing the potential for improvement in glycemic control.31,32  
This finding was also mirrored in the deviance analysis, where the positive deviants had 
notable higher baseline values [11.4, 13.6, 11.5, 13.4, 12.2, 15.9] than the negative deviants [8.8, 
8.1]. Additionally, baseline HbA1c differences may influence gender differences in HbA1c 
improvement, as women were found to have significantly lower baseline values than men 
(p=0.039).  
 
Readiness to Change 
The Stages of Change model suggests that a patient must be in the correct stage of 
readiness in order to act to change their behavior. The findings from this study align with this 
model, as patients who reported higher levels of readiness tended to experience larger 
improvements in A1c (p=0.08). This was mirrored in the deviance analysis, where positive 
deviants tended to have higher self-efficacy and readiness to change than the negative deviants. 
A similar study of a diabetes educational program found that patients with higher readiness to 
change experienced significantly larger improvements in HbA1c level after the intervention 
(p=0.006).33 In a survey of 617 patients with diabetes, researchers found that readiness to change 
significantly predicted future improvements in HbA1c levels.32 These studies corroborate the 
findings of this thesis. 
 
Barriers to Diabetes Management 
Patients most frequently reported work, comorbidities, cost, time, medication side effects, 
and cultural reasons as barriers to improving their glycemic control. The most highly cited 
literature around barriers focuses mainly on lack of social support, lack of knowledge about 
disease management, and cost issues that limit access to treatment.34,35 Medication side effects 
are also a well-documented barrier to medication adherence.7,36 There is relatively less literature 
on the relationship between diabetes and work, the second most highly cited barrier in this study. 
In addition, a majority of patients when asked about the hardest part of their diabetes cited diet. 
This aligns with strong evidence in the literature that dietary adherence in particular is a primary 
obstacle to glycemic control.35,37 
 
Significance and Implications 
This study demonstrated that important gender differences in diabetes management 
influence the extent to which women and men improve from an intervention. Related to gender, 
concordance is also an important predictor of glycemic control improvement. This study adds to 
the growing body of literature examining these differences, in which there is a lack of strong 
consensus around what drives gender differences in diabetes management and concordance.  
Researchers, healthcare organizations, insurers, and other stakeholders need to account 
for gender and concordance in the design of future interventions in order to both maximize the 
intervention effect and work to ensure equitable outcomes across genders. While it is important 
to recognize the power that these interventions have to address disparities across gender, race, 
and socioeconomic status, there is growing concern in the implementation science field about the 
unintentional effect that these trials could have on worsening gender disparities that already 
exist.38-40 This study emphasizes the importance of stratifying analyses by gender to fully 
understand an intervention’s effect on improving or exacerbating these disparities. These 
analyses are particularly timely, given calls to shift from the field’s predominant one-size-fits-all 
approach towards a greater focus on how subgroups within large trial populations benefit 
differentially from an intervention.41,42 
Patients in this sample cited work schedules and work environments as barriers that 
conflicted with their ability to eat healthy, exercise regularly, test their blood sugar, and visit a 
physician. While many workplace interventions for T2DM have been implemented, they are 
primarily educational and not structural.43 The findings of this study emphasize the existing need 
for stakeholders like employers and policymakers to develop policies that make it easier for 
diabetic employees to test their blood sugar during shifts, have breaks to exercise, or work in an 
environment with closer access to fitness equipment and healthy food choices.   
Finally, the deviance analysis illustrated key factors that may internally limit an 
intervention’s effect, such as patient subgroups that have low baseline HbA1c values and low 
self-efficacy or engagement with the intervention. These findings have implications for the 
design of similar future studies. Recruitment of a patient population that will maximally respond 
to a specific intervention and the consideration of factors like low-self-efficacy and engagement 
within the design of intervention are necessary to maximize an intervention’s potential effect and 
fully test its efficacy. 
 
Limitations 
A key limitation of this study is that several variables like barriers and self-management 
behaviors were self-reported by patients. Patients may have therefore under-reported or over-
reported these measures. It is unlikely that these varied differentially between those who 
improved and those who did not. However, this may have an effect for gender-stratified analyses 
as men may systematically under-report or over-report barriers and engagement in self-
management activities, such as diet and exercise levels, differently than women.44,45 
Additionally, the pharmacist notes were not a direct transcription of the conversation with 
the patient and may therefore have omitted information discussed during the call. Because of the 
semi-structured nature of the interview, data collected on variables was complete for some 
patients and not others, and descriptions varied in depth depending on the course of the telephone 
conversation. Despite this variation, the major concerns and decisions made by the patient were 
consistently notated by the pharmacists trained to implement this intervention.  
The ENGAGE-DM trial was not designed to detect significant differences in HbA1c 
change in patient subgroups and may not have been powered to detect all of these differences. 
By excluding patients with missing data and restricting the sample size to 155 patients, this 
study’s power to detect these differences was further reduced. In addition, the findings may have 
been confounded by variables like socioeconomic status and race that were not available in the 
insurance claims data. 
 
Future Directions 
The relationship between gender, concordance, and diabetes outcomes is complex and 
not adequately defined by current literature. Future studies are needed to target and more 
definitively characterize the relationship between these variables, particularly through a more 
qualitative approach. 
Further studies are also required to investigate work as a structural barrier to diabetes 
management, its relationship to gender, and perhaps its protective effect for male patients. This 
evidence could provide groundwork and more tangible goals for key stakeholders to implement 
effective structural workplace interventions, in conjunction with current educational strategies. 
Finally, this study examined a privately insured population of patients with diabetes and 
found that despite their coverage, some patients still faced important cost barriers that impeded 
their diabetes management. It is likely that the application of this study to an uninsured or 
publicly insured patient sample would give further insight into the different barriers they face, in 
order to develop a better understanding of disparities that exist and how clinical and policy 
interventions can better address them. 
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